(Q33944796)

30 July 2017

1 reference

title

Lipid lowering improves endothelial functions (English)

1 reference

30 July 2017

0 references

Libby P

1

1 reference

30 July 2017

Aikawa M

2

1 reference

30 July 2017

Kinlay S

3

1 reference

30 July 2017

Selwyn A

4

1 reference

30 July 2017

Ganz P

5

1 reference

30 July 2017

1 June 2000

1 reference

International Journal of Cardiology

30 July 2017

1 reference

30 July 2017

74 Suppl 1

1 reference

30 July 2017

S3-S10

1 reference

Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B

30 July 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2899%2900105-9

7 January 2021

Lipid lowering and plaque regression. New insights into prevention of plaque disruption and clinical events in coronary disease

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2899%2900105-9

7 January 2021

Effects on coronary artery disease of lipid-lowering diet, or diet plus cholestyramine, in the St Thomas' Atherosclerosis Regression Study (STARS)

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2899%2900105-9

7 January 2021

Coronary angiographic changes with lovastatin therapy. The Monitored Atherosclerosis Regression Study (MARS).

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2899%2900105-9

7 January 2021

Effects of monotherapy with an HMG-CoA reductase inhibitor on the progression of coronary atherosclerosis as assessed by serial quantitative arteriography. The Canadian Coronary Atherosclerosis Intervention Trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2899%2900105-9

7 January 2021

Pravastatin limitation of atherosclerosis in the coronary arteries (PLAC I): Reduction in atherosclerosis progression and clinical events

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2899%2900105-9

7 January 2021

Effects of lipid lowering by pravastatin on progression and regression of coronary artery disease in symptomatic men with normal to moderately elevated serum cholesterol levels. The Regression Growth Evaluation Statin Study (REGRESS)

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2899%2900105-9

7 January 2021

Adhesion molecules--Part II: Blood vessels and blood cells

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2899%2900105-9

7 January 2021

Signal transduction in atherosclerosis: integration of cytokines and the eicosanoid network

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2899%2900105-9

7 January 2021

Cytokines regulate genes involved in atherogenesis.

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2899%2900105-9

7 January 2021

Endothelial-leukocyte adhesion molecules

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2899%2900105-9

7 January 2021

Effects of endothelium-derived nitric oxide on peripheral arteriolar tone in man

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2899%2900105-9

7 January 2021

Comparative pharmacology of endothelium-derived relaxing factor, nitric oxide and prostacyclin in platelets

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2899%2900105-9

7 January 2021

Paradoxical vasoconstriction induced by acetylcholine in atherosclerotic coronary arteries

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2899%2900105-9

7 January 2021

Beneficial effect of cholesterol-lowering therapy on coronary endothelium-dependent relaxation in hypercholesterolaemic patients

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2899%2900105-9

7 January 2021

Reduction in serum cholesterol with pravastatin improves endothelium-dependent coronary vasomotion in patients with hypercholesterolemia

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2899%2900105-9

7 January 2021

The effect of cholesterol-lowering and antioxidant therapy on endothelium-dependent coronary vasomotion

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2899%2900105-9

7 January 2021

Beneficial effects of cholesterol-lowering therapy on the coronary endothelium in patients with coronary artery disease

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2899%2900105-9

7 January 2021

Reduction of transient myocardial ischemia with pravastatin in addition to the conventional treatment in patients with angina pectoris. REGRESS Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2899%2900105-9

7 January 2021

Effect of cholesterol reduction on myocardial ischemia in patients with coronary disease

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2899%2900105-9

7 January 2021

Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2899%2900105-9

7 January 2021

Relationship between plasma LDL concentrations during treatment with pravastatin and recurrent coronary events in the Cholesterol and Recurrent Events trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2899%2900105-9

7 January 2021

The effect of aggressive lowering of low-density lipoprotein cholesterol levels and low-dose anticoagulation on obstructive changes in saphenous-vein coronary-artery bypass grafts

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2899%2900105-9

7 January 2021

10.1016/S0167-5273(99)00105-9

Identifiers

DOI

1 reference

30 July 2017

1 reference